CLC, then CLC+BAM, then CLC+ABC for Type 1 Diabetes

Phase-Based Progress Estimates
Type 1 DiabetesCLC + BAM - Device
18 - 70
All Sexes
What conditions do you have?

Study Summary

This study is intended to test a Web-based Information Tool (WIT) software providing additional information regarding time in range, GMI, hypo- and hyperglycemia risks, variability tracker, daily glycemic profiles, and potential changes of insulin pump parameters, to users of a commercially available Closed-Loop Control (CLC) System (Control-IQ Technology).

Eligible Conditions
  • Type 1 Diabetes

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 4 weeks

4 weeks
CGM-measured coefficient of variation during the day
CGM-measured percent above 180 mg/dL during the day
CGM-measured percent below 70 mg/dL during the day
CGM-measured percent time in range 70-180 mg/dL

Trial Safety

Trial Design

2 Treatment Groups

CLC, then CLC+BAM, then CLC+ABC
1 of 2
CLC+ABC, then CLC+BAM, then CLC
1 of 2

Active Control

90 Total Participants · 2 Treatment Groups

Primary Treatment: CLC, then CLC+BAM, then CLC+ABC · No Placebo Group · N/A

CLC, then CLC+BAM, then CLC+ABCActiveComparator Group · 2 Interventions: CLC + BAM, CLC + ABC · Intervention Types: Device, Device
CLC+ABC, then CLC+BAM, then CLCActiveComparator Group · 2 Interventions: CLC + BAM, CLC + ABC · Intervention Types: Device, Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4 weeks

Who is running the clinical trial?

Sue BrownLead Sponsor
1 Previous Clinical Trials
6 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,148 Previous Clinical Trials
4,074,659 Total Patients Enrolled
Tandem Diabetes Care, Inc.Industry Sponsor
34 Previous Clinical Trials
4,040 Total Patients Enrolled
Sue Brown, MDPrincipal InvestigatorUniversity of Virginia Center for Diabetes Technology
14 Previous Clinical Trials
926 Total Patients Enrolled

Eligibility Criteria

Age 18 - 70 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be at least 18 years old at the time of consent.
You are using or willing to use insulin parameters such as carbohydrate ratio and correction factors consistently on your pump in order to dose insulin for meals or corrections.
You have access to the internet and you are willing to upload data during the study as needed.